[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Wei Zhao\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":64},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100350557","phase-4-dose-individualization-of-antineoplastic-drugs-and-anti-infective-drug-in-children-with-hematoplastic-disease-100350557",false,"NCT03844360","Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease","Inclusion Criteria:\n\n* Patients must be diagnosed with hematological neoplasms\n* Antineoplastic drugs or anti-infective drugs used as part of regular treatment\n\nExclusion Criteria:\n\n* expected survival time less than the treatment cycle;\n* patients with other factors that researcher considers unsuitable for inclusion.","ALL","1 Day","18 Years",{"count":19,"type":20},1500,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.",[26],"Hematological Neoplasms","RECRUITING","2025-03-25",{"date":30,"type":31},"2025-03-30","ACTUAL",{"date":33,"type":31},"2016-01-31",{"date":35,"type":20},"2026-12-31",{"name":37,"class":38},"Wei Zhao","OTHER",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":50,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100474568","antiepileptic-drugs-in-elderly-patients-100474568","NCT05459597","Antiepileptic Drugs in Elderly Patients","Population Pharmacokinetics, Effectiveness and Safety of Antiepileptic Drugs in Elderly Patients","Inclusion Criteria:\n\n1. Age ≥65 years old;\n2. Diagnosed with epilepsy;\n3. Using antiepileptic drugs for treatment;\n\nExclusion Criteria:\n\n1. Patients who are expected to die within 48 hours;\n2. Patients with allergy to antiepileptic drugs;\n3. Patients receiving other investigational drugs;\n4. Other factors that the researcher considers unsuitable for inclusion.","65 Years","100 Years",{"count":49,"type":20},500,"3 Days","OBSERVATIONAL","The purpose is to study the population pharmacokinetics, effectiveness and safety of antiepileptic drug (phenytoin, carbamazepine, lamotrigine, levetiracetam, parempanel, etc) in elderly patients and recommend optimized dosage regimens.",[54],"Seizure, Epileptic","2022-07-14",{"date":57,"type":31},"2022-07-15",{"date":59,"type":31},"2021-01-01",{"date":61,"type":20},"2028-06-30",{"name":37,"class":38},1,""]